JP2021536474A5 - - Google Patents

Info

Publication number
JP2021536474A5
JP2021536474A5 JP2021512694A JP2021512694A JP2021536474A5 JP 2021536474 A5 JP2021536474 A5 JP 2021536474A5 JP 2021512694 A JP2021512694 A JP 2021512694A JP 2021512694 A JP2021512694 A JP 2021512694A JP 2021536474 A5 JP2021536474 A5 JP 2021536474A5
Authority
JP
Japan
Prior art keywords
sustained
pharmaceutical composition
therapeutic agent
ophthalmic pharmaceutical
release ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021512694A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021536474A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/050135 external-priority patent/WO2020055713A1/en
Publication of JP2021536474A publication Critical patent/JP2021536474A/ja
Publication of JP2021536474A5 publication Critical patent/JP2021536474A5/ja
Ceased legal-status Critical Current

Links

JP2021512694A 2018-09-10 2019-09-09 徐放性眼科用医薬組成物およびその使用 Ceased JP2021536474A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729038P 2018-09-10 2018-09-10
US62/729,038 2018-09-10
PCT/US2019/050135 WO2020055713A1 (en) 2018-09-10 2019-09-09 Sustained-release ophthalmic pharmaceutical compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2021536474A JP2021536474A (ja) 2021-12-27
JP2021536474A5 true JP2021536474A5 (enExample) 2022-09-08

Family

ID=69778306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512694A Ceased JP2021536474A (ja) 2018-09-10 2019-09-09 徐放性眼科用医薬組成物およびその使用

Country Status (6)

Country Link
US (1) US20210275447A1 (enExample)
EP (1) EP3849523A4 (enExample)
JP (1) JP2021536474A (enExample)
CN (1) CN112654345A (enExample)
TW (1) TWI786328B (enExample)
WO (1) WO2020055713A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
IL330178A (en) 2024-01-03 2026-08-01 LYOTROPIC DELIVERY SYSTEMS Ltd Topical formulations for delivering active ingredients to the back of the eye

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140892A0 (en) * 1998-08-12 2002-02-10 Yissum Res Dev Co Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
US8753673B2 (en) * 2006-05-23 2014-06-17 Taiwan Liposome Co. Ltd. Liposome composition for delivery of a therapeutic agent to eyes
US20080118500A1 (en) * 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
CN101199505B (zh) * 2007-12-20 2012-05-23 沈阳药科大学 维拉帕米脂质体及其制备方法
CN101601654B (zh) * 2009-07-03 2010-08-18 王明 盐酸法舒地尔脂质体注射剂及其新应用
CN102485212B (zh) * 2010-12-01 2014-04-09 沈阳药科大学 苹果酸舒尼替尼脂质体及其制备方法
CN109350600B (zh) * 2013-03-15 2021-10-29 台湾微脂体股份有限公司 设计脂质体水相和非水相部分的组成来控制药物的释放趋势
CN106999419A (zh) * 2014-08-04 2017-08-01 佐尼奥尼制药股份有限公司 远程装载略微水溶性药物至脂质膜泡
TWI664965B (zh) * 2015-06-22 2019-07-11 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法
CN108295072A (zh) * 2015-12-09 2018-07-20 瑞阳(苏州)生物科技有限公司 尼达尼布防治眼部疾病的用途
WO2017120537A1 (en) * 2016-01-08 2017-07-13 The Regents Of The University Of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
CN106727325A (zh) * 2016-12-29 2017-05-31 青岛黄海制药有限责任公司 一种甲磺酸伊马替尼的脂质体制剂及其制备方法
US11534399B2 (en) * 2018-04-23 2022-12-27 Inspirmed Corp. Inhalable liposomal sustained release composition for use in treating pulmonary diseases
WO2020023445A1 (en) * 2018-07-24 2020-01-30 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof

Similar Documents

Publication Publication Date Title
TWI866908B (zh) 用於治療肺部疾病的可吸入的緩釋組成物
JP2019023243A5 (enExample)
CN104125830B (zh) 用以减少眼用类固醇的并发症的药物组合物
JP2022502451A5 (enExample)
TW201105350A (en) Ophthalmic drug delivery system containing phospholipid and cholesterol
US20040224010A1 (en) Ophthalmic liposome compositions and uses thereof
RU2014120216A (ru) Комбинационные липосомальные композиции для лечения рака
BRPI0707059A2 (pt) método de formação de uma micela que compreende oxaliplatina, método de encapsulação de oxaliplatina em um lipossomo, micela, lipossomo, lipossomo que compreende uma quantidade eficaz de oxaliplatina, uso de um lipossomo, método de tratamento de cáncer e terapia de combinação
JP6230538B2 (ja) 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
JP2019516693A5 (enExample)
TWI786328B (zh) 緩釋眼用藥物組合物及其用途
TWI767133B (zh) 含有治療憂鬱症或焦慮症之治療劑的緩釋組合物及其用途
JP2019515925A (ja) 炎症性病変又は領域に局所注射するためのリポソーム化コルチコステロイド
JP2022500398A5 (enExample)
ES3058285T3 (en) Pharmaceutical compositions with reduced side effect and methods of using the same
JP2023030106A5 (enExample)
US9078812B2 (en) Particulate drug carriers as desensitizing agents
TW202143978A (zh) 格列本脲脂質體組合物及其製備方法
KR101305721B1 (ko) 신생 혈관 생성 및 신생 림프관 생성 억제를 위한 설린닥의 신규한 제형 및 이를 포함하는 안질환의 치료용 조성물
US20070148225A1 (en) PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
JP2022505378A5 (enExample)
TW202220668A (zh) 用於疼痛控制之關節內皮質類固醇的藥學組成物
HK40043569A (en) Inhalable liposomal sustained release composition for use in treating pulmonary diseases
RU2020102279A (ru) Липосомальные композиции, содержащие слабокислотные лекарственные средства, и их применение